

Unless otherwise defined in this announcement, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 7, 2017 (the “**Prospectus**”) issued by AK Medical Holdings Limited (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”). The Shares may not be offered or sold in the United States except pursuant to an effective registration statement or an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Shares in the United States.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities of the Company. Potential investors should read the Prospectus for detailed information about the Company before deciding whether or not to invest in the Shares thereby offered.



AK MEDICAL HOLDINGS LIMITED

愛康醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1789)

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-Allotment Option described in the Prospectus was fully exercised by the Sole Global Coordinator (on behalf of the International Underwriters) on December 27, 2017 in respect of 37,500,000 additional Shares (the “**Over-Allotment Shares**”), representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-Allotment Option). The Over-Allotment Shares will be allotted and issued by the Company at HK\$1.75 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

Further announcement will be made by the Company after the end of the stabilization period.

The Company announces that the Over-Allotment Option described in the Prospectus was fully exercised by the Sole Global Coordinator (on behalf of the International Underwriters) on December 27, 2017 in respect of the Over-Allotment Shares, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-Allotment Option).

Pursuant to the Stock Borrowing Agreement, Goldman Sachs International has borrowed 37,500,000 Shares from Ximalaya Limited (“**Ximalaya**”) to cover over-allocations in the International Placing. The Over-Allotment Shares will be used to facilitate the return in full to Ximalaya of the 37,500,000 borrowed Shares, which were used solely to cover over-allocations in the International Placing.

The Over-Allotment Shares will be allotted and issued by the Company at HK\$1.75 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

Approval for the listing of and permission to deal in the Over-Allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in such Over-Allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on January 4, 2018.

The shareholding structure of the Company immediately before and immediately after the completion of the allotment and issue by the Company of the Over-Allotment Shares is as follows:

Shareholders	Immediately before the allotment and issue of the Over-Allotment Shares		Immediately after the allotment and issue of the Over-Allotment Shares	
	Number of Shares	Approximate percentage of the Company's issued share capital	Number of Shares	Approximate percentage of the Company's issued share capital
Ximalaya ⁽¹⁾	585,157,500	58.51575%	585,157,500	56.40072%
OrbiMed Asia ⁽²⁾	75,000,000	7.50000%	75,000,000	7.22892%
Suntop ⁽³⁾	67,432,500	6.74325%	67,432,500	6.49952%
Sanbao ⁽⁴⁾	12,285,000	1.22850%	12,285,000	1.18410%
Summer ⁽⁵⁾	10,125,000	1.01250%	10,125,000	0.97590%
Other Shareholders	250,000,000	25.00000%	287,500,000	27.71084%

Notes:

1. Ximalaya is owned as to 50% by Mr. Li Zhijiang (“**Mr. Li**”) and as to 50% under the Family Trust. The Family Trust is a discretionary trust established by Mr. Li as settlor, with Trident Trust acting as trustee. The beneficiaries of the Family Trust are Mr. Li and certain of his family members. Trident Trust holds 100% of the issued share capital of Rainbow Holdings, which holds 50% of the issued share capital of Ximalaya under the Family Trust. Therefore, each of Mr. Li, Trident Trust, Rainbow Holdings is deemed to be interested in Ximalaya’s interest in the 585,157,500 Shares pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”). In addition, Mr. Li is the husband of Ms. Zhang Bin. Therefore, Mr. Li is deemed to be interested in Ms. Zhang Bin’s interest in our Shares pursuant to the SFO.
2. The general partner of OrbiMed Asia is OrbiMed Asia GP II, L.P., whose general partner is OrbiMed Advisors II Limited. Therefore, each of OrbiMed Asia GP II, L.P. and OrbiMed Advisors II Limited is deemed to be interested in OrbiMed Asia’s interest in the 75,000,000 Shares pursuant to the SFO.
3. Mr. Zhang Chaoyang is the sole shareholder of Suntop which holds 67,432,500 Shares. Therefore, Mr. Zhang Chaoyang is deemed to be interested in Suntop’s interest in our Shares pursuant to the SFO. Mr. Zhang Chaoyang is the brother of Ms. Zhang Bin and the brother-in-law of Mr. Li.
4. Sanbao is owned as to 30.22% by Ms. Zhao Xiaohong.
5. Ms. Zhang Bin is the sole shareholder of Summer which holds 10,125,000 Shares. Therefore, Ms. Zhang Bin is deemed to be interested in Summer’s interest in our Shares pursuant to the SFO. In addition, Ms. Zhang Bin is the wife of Mr. Li. Therefore, Ms. Zhang Bin is deemed to be interested in Mr. Li’s interest in our Shares pursuant to the SFO.

The additional net proceeds of approximately HK\$62.3 million from the issue of the Over-Allotment Shares after deducting the underwriting commission, incentive fee and estimated expenses relating to the exercise of the Over-Allotment Option will be used by the Company for the purposes as set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus.

Immediately after the allotment and issue of the Over-Allotment Shares, the Company will continue to comply with the public float requirements under Rule 8.08 of the Listing Rules.

A further announcement will be made by the Company at the end of the stabilization period in connection with the Global Offering pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

By order of the Board of Director
AK Medical Holdings Limited
Li Zhijiang
Chairman

Hong Kong, December 27, 2017

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive Directors, Mr. Li Wenming and Mr. Wang David Guowei as non-executive Directors, and Mr. Dang Gengting, Mr. Kong Chi Mo and Mr. Li Shu Wing David as independent non-executive Directors.